The company, part of BioSig Technologies, aims to run a Phase II study of the drug, merimepodib, which had previously failed in a Phase IIb HCV study run by Vertex Pharmaceuticals. The company hopes the drug’s mechanism could prove effective against SARS-CoV-2.

LEAVE A REPLY

Please enter your comment!
Please enter your name here